Oncology Scientific Publication 

ADCs in HER2+ metastatic breast cancer and management of adverse events

Consensus-based guidance for clinicians and patients

Prof. Javier Cortés

Prof. Javier Cortés
Prof. Giuseppe Curigliano

Prof. Giuseppe Curigliano
Prof. Shaheenah Dawood

Prof. Shaheenah Dawood
Dr Grażyna Suchodolska

Dr Grażyna Suchodolska
Dr Sara Tolaney

Dr Sara Tolaney
Carla Whitbread

Carla Whitbread
Publication Date

Feb 2026

info Summary and next episodes download Downloadable resources

T-DXd is a key treatment option for patients with HER2-positive metastatic breast cancer (mBC), with its safety profile often described as “manageable.” However, clinicians and patients still need clear, practical guidance on how to manage treatment-related adverse events (TRAE) in everyday practice, from most frequent toxicities such as nausea, vomiting, and fatigue, to the rare but clinically critical risk of interstitial lung disease (ILD).

 

An international multidisciplinary panel has developed guidance-at-a-glance; step-by-step strategies to support effective management of T-DXd–related adverse events in HER2+ mBC.

 

The experts share:

  • An overview of the current treatment landscape in HER2+ mBC
  • Practical approaches to managing most frequent TRAE, including nausea, vomiting, and fatigue
  • Best practices for recognising, monitoring and responding to ILD, including escalation pathways
  • A dedicated one-page patient resource to support awareness and shared decision-making

 

Download the paper to move beyond describing toxicities as “manageable” and know how to apply practical strategies in routine care.

 

 

Clinical takeaways

  • T-DXd is a highly emetogenic agent, warranting prophylaxis with a 3-drug regimen: a 5-HT3 RA, NK1 RA, and dexamethasone. A 4-drug regimen including olanzapine is recommended if prior 3-drug prophylaxis was inadequate or for patients at high-risk (e.g. younger age, history of CINV, anxiety, hyperemesis during pregnancy)
  • As breakthrough nausea and vomiting may occur despite prophylaxis—within 5 days (acute) or between days 6–21 (delayed) post–T-DXd—upfront prescribing of olanzapine is recommended for potential acute or delayed symptoms, and ondansetron as an alternative for delayed nausea, to enable as-needed use
  • Fatigue associated with T-DXd should be proactively managed through routine screening, assessment of reversible causes, patient education, exercise, supportive care, and dose adjustments when needed
  • ILD is a potentially serious adverse event with T-DXd and should be addressed using the 5S approach: Screen regularly, scan early, synergise with the patient and MDT, suspend treatment if ILD is suspected, and initiate steroids promptly if ILD is suspected
  • Understand the role of ADCs in breast cancer treatment
    • ADCs for HER2-positive mBC
    • International treatment guidelines
  • Be able to identify and manage adverse events linked to next-generation HER2-targeted ADC
    • Recognise the most common AEs associated with T-DXd, with a focus on nausea and vomiting, and acknowledgment of fatigue
    • Implement evidence-based strategies for monitoring, dose modifications, and supportive care to optimise patient safety

Head of the International Breast Cancer Centre (IBCC) in Barcelona, founding partner of Medica Scientia innovation Research (MedSIR), a company involved in the clinical development of clinical trials. Member of the Scientific Committee of the ESMO and EBCC.

Prof. Javier Cortés has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Roche , AstraZeneca, Seattle Genetics, Daiichi Sankyo, Lilly, Merck Sharp & Dohme, Leuko, Bioasis, Clovis Oncology, Boehringer Ingelheim, Ellipses, Hibercell, BioInvent, Gemoab, Gilead, Menarini, Zymeworks, Reveal Genomics, Scorpion Therapeutics, Expres2ion Biotechnologies, Jazz Pharmaceuticals, Abbvie, BridgeBio, Biontech, Biocon, Circle Pharma, Delcath Systems, Roche, Novartis, Eisai, Pfizer, Lilly, Merck Sharp & Dohme, Daiichi Sankyo, Astrazeneca, Gilead, Stemline Therapeutics.

Director of the Early Drug Development Division and Co-Chair for the Experimental Therapeutics Program at the European Institute of Oncology, a comprehensive cancer center in Milan, Italy. He is a steering committee member of the Department of Oncology and Hemato-Oncology at the University of Milan. Moreover, he is a member of the Italian National Health Council, serving as an adviser to the Ministry of Health for cancer policy issues.

Prof. Giuseppe Curigliano has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

AstraZeneca, BMS, Celcuity, Daiichi Sankyo, Exact Sciences, Menarini, Merck, Novartis, Pfizer, Roche, Ellipsis, Astellas, Blueprint Medicines, BMS, Kymab, Philogen, Relay Therapeutics and Sanofi​

Shaheenah Dawood is a Consultant medical oncologist and professor in clinical oncology in the United Arab Emirates. She trained in medical oncology at McGill University Hospitals in Canada and subspecialized in breast cancer management at MD Anderson Cancer Center. During her training she was awarded multiple scholar in training awards and ASCO merit awards. She has served as an editorial fellow at the New England Journal of medicine and has an MPH from the Harvard School of Public Health. She has over 100 papers to her credit including 50 peer review original articles, 30 review articles and 12 book chapters. She serves as a reviewer for multiple journals. She currently leads the oncology clinical trials program at Mediclinic City Hospital Dubai. She also serves as president of the Excellence in oncology summit that is held annually in Dubai and is co president of the Asia pacific breast cancer summit (ABCS) and Asia pacific gastrointestinal cancer summit (APGCS). She has also recently launched the international BRCA forum and young womens forum.

Prof. Shaheenah Dawood has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

MSD, Roche, BMS, New Bridge, Novartis, llilly , Pfizer, Caris, Merck, Jaansen, Ipsen,Astrazeneca, Zulleg Pharma

Bio- Grażyna began her nursing career in 2005, gaining clinical experience in critical care, emergency medicine, and oncology. Grażyna is the Specialist Oncology Nurse and was the first Breast Cancer Nurse in Poland. Since 2018, she has remained dedicated to this role, currently working in Breast Cancer Chemotherapy Day Unit at the University Clinical Centre in Gdańsk.

 

 

In 2023, Grażyna accomplished her PhD at the Medical University of Gdańsk, where she continues to share her expertise and passion for breast cancer with nursing and medical students as a lecturer.  

 

 

Beyond her clinical role, Grażyna actively advocates for breast cancer nursing in Poland and participates in initiatives aimed at raising awareness about breast cancer and its prevention among Polish women. She is a member of the Polish Society of Oncology and holds the position of Vice President for the local Polish Oncology Nurses Association.

Sara Tolaney, MD, MPH is the Chief of the Division of Breast Oncology at Dana-Farber Cancer Institute, and is internationally recognized for her research and education leadership in breast cancer. She also serves as Associate Director of the Susan F. Smith Center for Women’s Cancers and is a Senior Physician at Dana-Farber Cancer Institute and Associate Professor of Medicine at Harvard Medical School.

Dr Tolaney received her undergraduate degree from Princeton University and her medical degree from UC San Francisco. She subsequently completed her residency in Internal Medicine at Johns Hopkins University, and fellowships in hematology and medical oncology at Dana-Farber Cancer Institute. She obtained her Masters in Public Health from Harvard School of Public Health.

Her research focuses on the development of novel therapies in the treatment of breast cancer and developing more effective and less toxic treatment approaches. Her work has demonstrated that a relatively low risk regimen is beneficial in women with early stage node-negative HER2-positive cancers, and this works has been incorporated into national and international guidelines. She has developed several follow-up studies looking at novel approaches to early stage HER2-positive disease and has also played a significant role in development of cdk 4/6 inhibitors, antibody drug conjugates, and immunotherapy in breast cancer. She currently chairs several registration studies in these areas and also leads many investigator-initiated trials. She is the author of over 150 peer-reviewed publications with manuscripts included in many prestigious journals such as the New England Journal, Lancet Oncology, Journal of Clinical Oncology, and JAMA Oncology.

Dr Sara Tolaney has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Consulting or Advisory Role: Novartis, Pfizer, Merck, Eli Lilly, AstraZeneca, Genentech/Roche, Eisai, Sanofi, Bristol Myers Squibb, Seattle Genetics, CytomX Therapeutics, Daiichi Sankyo, Gilead, Ellipses Pharma, 4D Pharma, OncoSec Medical Inc., BeyondSpring Pharmaceuticals, OncXerna, Zymeworks, Zentalis, Blueprint Medicines, Reveal Genomics, ARC Therapeutics, Infinity Therapeutics, Myovant, Zetagen, Umoja Biopharma, Menarini/Stemline, Aadi Biopharma, Bayer

Research Funding: Genentech/Roche, Merck, Exelixis, Pfizer, Lilly, Novartis, Bristol Myers Squibb, Eisai, AstraZeneca, Gilead, NanoString Technologies, Gilead, Seattle Genetics, OncoPep

Carla Whitbread became a breast cancer patient representative and advocate following her diagnosis of Metastatic Breast Cancer (MBC) de novo in 2011, at the age of 37. Driven by her experience, Carla is dedicated to raising awareness of MBC and advocating for improved cancer services to enhance survival rates and quality of life for those affected by the disease. Locally, Carla serves as the ambassador of Força – Strength Against Cancer, a UK-registered charity that supports the physical and mental well-being of individuals living with or affected by cancer. She also plays an integral role in Wessex Cancer Alliance’s Patient and Public Involvement Steering Group. Nationally, Carla is an Executive Committee Member of Europa Donna UK. In October 2024, she was elected Europa Donna’s Alternate Representative to the ABC Global Alliance Board of Directors. Additionally, she contributes to the Audit Advisory Committee for NaoME (National Audit of Metastatic Breast Cancer) as a Patient Representative. In 2023, Carla was one of five faces of The Cancer Currency, a pan-European campaign that aims to prioritise metastatic breast cancer and underscore the value of women living with the disease. Through her work, Carla continues to drive change in the MBC community, advocating for greater awareness, better services, and hope for the future.

pdf Download BluePrint - PDF clock

T-DXd is a key treatment option for patients with HER2-positive metastatic breast cancer (mBC), with its safety profile often described as “manageable.” However, clinicians and patients still need clear, practical guidance on how to manage treatment-related adverse events (TRAE) in everyday practice, from most frequent toxicities such as nausea, vomiting, and fatigue, to the rare but clinically critical risk of interstitial lung disease (ILD).

 

An international multidisciplinary panel has developed guidance-at-a-glance; step-by-step strategies to support effective management of T-DXd–related adverse events in HER2+ mBC.

 

The experts share:

  • An overview of the current treatment landscape in HER2+ mBC
  • Practical approaches to managing most frequent TRAE, including nausea, vomiting, and fatigue
  • Best practices for recognising, monitoring and responding to ILD, including escalation pathways
  • A dedicated one-page patient resource to support awareness and shared decision-making

 

Download the paper to move beyond describing toxicities as “manageable” and know how to apply practical strategies in routine care.

 

 

Clinical takeaways

  • T-DXd is a highly emetogenic agent, warranting prophylaxis with a 3-drug regimen: a 5-HT3 RA, NK1 RA, and dexamethasone. A 4-drug regimen including olanzapine is recommended if prior 3-drug prophylaxis was inadequate or for patients at high-risk (e.g. younger age, history of CINV, anxiety, hyperemesis during pregnancy)
  • As breakthrough nausea and vomiting may occur despite prophylaxis—within 5 days (acute) or between days 6–21 (delayed) post–T-DXd—upfront prescribing of olanzapine is recommended for potential acute or delayed symptoms, and ondansetron as an alternative for delayed nausea, to enable as-needed use
  • Fatigue associated with T-DXd should be proactively managed through routine screening, assessment of reversible causes, patient education, exercise, supportive care, and dose adjustments when needed
  • ILD is a potentially serious adverse event with T-DXd and should be addressed using the 5S approach: Screen regularly, scan early, synergise with the patient and MDT, suspend treatment if ILD is suspected, and initiate steroids promptly if ILD is suspected
  • Understand the role of ADCs in breast cancer treatment
    • ADCs for HER2-positive mBC
    • International treatment guidelines
  • Be able to identify and manage adverse events linked to next-generation HER2-targeted ADC
    • Recognise the most common AEs associated with T-DXd, with a focus on nausea and vomiting, and acknowledgment of fatigue
    • Implement evidence-based strategies for monitoring, dose modifications, and supportive care to optimise patient safety

Carla Whitbread became a breast cancer patient representative and advocate following her diagnosis of Metastatic Breast Cancer (MBC) de novo in 2011, at the age of 37. Driven by her experience, Carla is dedicated to raising awareness of MBC and advocating for improved cancer services to enhance survival rates and quality of life for those affected by the disease. Locally, Carla serves as the ambassador of Força – Strength Against Cancer, a UK-registered charity that supports the physical and mental well-being of individuals living with or affected by cancer. She also plays an integral role in Wessex Cancer Alliance’s Patient and Public Involvement Steering Group. Nationally, Carla is an Executive Committee Member of Europa Donna UK. In October 2024, she was elected Europa Donna’s Alternate Representative to the ABC Global Alliance Board of Directors. Additionally, she contributes to the Audit Advisory Committee for NaoME (National Audit of Metastatic Breast Cancer) as a Patient Representative. In 2023, Carla was one of five faces of The Cancer Currency, a pan-European campaign that aims to prioritise metastatic breast cancer and underscore the value of women living with the disease. Through her work, Carla continues to drive change in the MBC community, advocating for greater awareness, better services, and hope for the future.

Bio- Grażyna began her nursing career in 2005, gaining clinical experience in critical care, emergency medicine, and oncology. Grażyna is the Specialist Oncology Nurse and was the first Breast Cancer Nurse in Poland. Since 2018, she has remained dedicated to this role, currently working in Breast Cancer Chemotherapy Day Unit at the University Clinical Centre in Gdańsk.

 

 

In 2023, Grażyna accomplished her PhD at the Medical University of Gdańsk, where she continues to share her expertise and passion for breast cancer with nursing and medical students as a lecturer.  

 

 

Beyond her clinical role, Grażyna actively advocates for breast cancer nursing in Poland and participates in initiatives aimed at raising awareness about breast cancer and its prevention among Polish women. She is a member of the Polish Society of Oncology and holds the position of Vice President for the local Polish Oncology Nurses Association.

Director of the Early Drug Development Division and Co-Chair for the Experimental Therapeutics Program at the European Institute of Oncology, a comprehensive cancer center in Milan, Italy. He is a steering committee member of the Department of Oncology and Hemato-Oncology at the University of Milan. Moreover, he is a member of the Italian National Health Council, serving as an adviser to the Ministry of Health for cancer policy issues.

Prof. Giuseppe Curigliano has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

AstraZeneca, BMS, Celcuity, Daiichi Sankyo, Exact Sciences, Menarini, Merck, Novartis, Pfizer, Roche, Ellipsis, Astellas, Blueprint Medicines, BMS, Kymab, Philogen, Relay Therapeutics and Sanofi​

Head of the International Breast Cancer Centre (IBCC) in Barcelona, founding partner of Medica Scientia innovation Research (MedSIR), a company involved in the clinical development of clinical trials. Member of the Scientific Committee of the ESMO and EBCC.

Prof. Javier Cortés has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Roche , AstraZeneca, Seattle Genetics, Daiichi Sankyo, Lilly, Merck Sharp & Dohme, Leuko, Bioasis, Clovis Oncology, Boehringer Ingelheim, Ellipses, Hibercell, BioInvent, Gemoab, Gilead, Menarini, Zymeworks, Reveal Genomics, Scorpion Therapeutics, Expres2ion Biotechnologies, Jazz Pharmaceuticals, Abbvie, BridgeBio, Biontech, Biocon, Circle Pharma, Delcath Systems, Roche, Novartis, Eisai, Pfizer, Lilly, Merck Sharp & Dohme, Daiichi Sankyo, Astrazeneca, Gilead, Stemline Therapeutics.

Sara Tolaney, MD, MPH is the Chief of the Division of Breast Oncology at Dana-Farber Cancer Institute, and is internationally recognized for her research and education leadership in breast cancer. She also serves as Associate Director of the Susan F. Smith Center for Women’s Cancers and is a Senior Physician at Dana-Farber Cancer Institute and Associate Professor of Medicine at Harvard Medical School.

Dr Tolaney received her undergraduate degree from Princeton University and her medical degree from UC San Francisco. She subsequently completed her residency in Internal Medicine at Johns Hopkins University, and fellowships in hematology and medical oncology at Dana-Farber Cancer Institute. She obtained her Masters in Public Health from Harvard School of Public Health.

Her research focuses on the development of novel therapies in the treatment of breast cancer and developing more effective and less toxic treatment approaches. Her work has demonstrated that a relatively low risk regimen is beneficial in women with early stage node-negative HER2-positive cancers, and this works has been incorporated into national and international guidelines. She has developed several follow-up studies looking at novel approaches to early stage HER2-positive disease and has also played a significant role in development of cdk 4/6 inhibitors, antibody drug conjugates, and immunotherapy in breast cancer. She currently chairs several registration studies in these areas and also leads many investigator-initiated trials. She is the author of over 150 peer-reviewed publications with manuscripts included in many prestigious journals such as the New England Journal, Lancet Oncology, Journal of Clinical Oncology, and JAMA Oncology.

Dr Sara Tolaney has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Consulting or Advisory Role: Novartis, Pfizer, Merck, Eli Lilly, AstraZeneca, Genentech/Roche, Eisai, Sanofi, Bristol Myers Squibb, Seattle Genetics, CytomX Therapeutics, Daiichi Sankyo, Gilead, Ellipses Pharma, 4D Pharma, OncoSec Medical Inc., BeyondSpring Pharmaceuticals, OncXerna, Zymeworks, Zentalis, Blueprint Medicines, Reveal Genomics, ARC Therapeutics, Infinity Therapeutics, Myovant, Zetagen, Umoja Biopharma, Menarini/Stemline, Aadi Biopharma, Bayer

Research Funding: Genentech/Roche, Merck, Exelixis, Pfizer, Lilly, Novartis, Bristol Myers Squibb, Eisai, AstraZeneca, Gilead, NanoString Technologies, Gilead, Seattle Genetics, OncoPep

Shaheenah Dawood is a Consultant medical oncologist and professor in clinical oncology in the United Arab Emirates. She trained in medical oncology at McGill University Hospitals in Canada and subspecialized in breast cancer management at MD Anderson Cancer Center. During her training she was awarded multiple scholar in training awards and ASCO merit awards. She has served as an editorial fellow at the New England Journal of medicine and has an MPH from the Harvard School of Public Health. She has over 100 papers to her credit including 50 peer review original articles, 30 review articles and 12 book chapters. She serves as a reviewer for multiple journals. She currently leads the oncology clinical trials program at Mediclinic City Hospital Dubai. She also serves as president of the Excellence in oncology summit that is held annually in Dubai and is co president of the Asia pacific breast cancer summit (ABCS) and Asia pacific gastrointestinal cancer summit (APGCS). She has also recently launched the international BRCA forum and young womens forum.

Prof. Shaheenah Dawood has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

MSD, Roche, BMS, New Bridge, Novartis, llilly , Pfizer, Caris, Merck, Jaansen, Ipsen,Astrazeneca, Zulleg Pharma
pdf Download BluePrint - PDF clock

T-DXd is a key treatment option for patients with HER2-positive metastatic breast cancer (mBC), with its safety profile often described as “manageable.” However, clinicians and patients still need clear, practical guidance on how to manage treatment-related adverse events (TRAE) in everyday practice, from most frequent toxicities such as nausea, vomiting, and fatigue, to the rare but clinically critical risk of interstitial lung disease (ILD).

 

An international multidisciplinary panel has developed guidance-at-a-glance; step-by-step strategies to support effective management of T-DXd–related adverse events in HER2+ mBC.

 

The experts share:

  • An overview of the current treatment landscape in HER2+ mBC
  • Practical approaches to managing most frequent TRAE, including nausea, vomiting, and fatigue
  • Best practices for recognising, monitoring and responding to ILD, including escalation pathways
  • A dedicated one-page patient resource to support awareness and shared decision-making

 

Download the paper to move beyond describing toxicities as “manageable” and know how to apply practical strategies in routine care.

 

 

Clinical takeaways

 

  • T-DXd is a highly emetogenic agent, warranting prophylaxis with a 3-drug regimen: a 5-HT3 RA, NK1 RA, and dexamethasone. A 4-drug regimen including olanzapine is recommended if prior 3-drug prophylaxis was inadequate or for patients at high-risk (e.g. younger age, history of CINV, anxiety, hyperemesis during pregnancy)
  • As breakthrough nausea and vomiting may occur despite prophylaxis—within 5 days (acute) or between days 6–21 (delayed) post–T-DXd—upfront prescribing of olanzapine is recommended for potential acute or delayed symptoms, and ondansetron as an alternative for delayed nausea, to enable as-needed use
  • Fatigue associated with T-DXd should be proactively managed through routine screening, assessment of reversible causes, patient education, supportive care, and dose adjustments when needed
  • ILD is a potentially serious adverse event with T-DXd and should be addressed using the 5S approach: Screen regularly, scan early, synergise with the patient and MDT, suspend treatment if ILD is suspected, and initiate steroids promptly if ILD is suspected

 

  • Understand the role of ADCs in breast cancer treatment
    • ADCs for HER2-positive mBC
    • International treatment guidelines
  • Be able to identify and manage adverse events linked to next-generation HER2-targeted ADC
    • Recognise the most common AEs associated with T-DXd, with a focus on nausea and vomiting, and acknowledgment of fatigue
    • Implement evidence-based strategies for monitoring, dose modifications, and supportive care to optimise patient safety

Carla Whitbread became a breast cancer patient representative and advocate following her diagnosis of Metastatic Breast Cancer (MBC) de novo in 2011, at the age of 37. Driven by her experience, Carla is dedicated to raising awareness of MBC and advocating for improved cancer services to enhance survival rates and quality of life for those affected by the disease. Locally, Carla serves as the ambassador of Força – Strength Against Cancer, a UK-registered charity that supports the physical and mental well-being of individuals living with or affected by cancer. She also plays an integral role in Wessex Cancer Alliance’s Patient and Public Involvement Steering Group. Nationally, Carla is an Executive Committee Member of Europa Donna UK. In October 2024, she was elected Europa Donna’s Alternate Representative to the ABC Global Alliance Board of Directors. Additionally, she contributes to the Audit Advisory Committee for NaoME (National Audit of Metastatic Breast Cancer) as a Patient Representative. In 2023, Carla was one of five faces of The Cancer Currency, a pan-European campaign that aims to prioritise metastatic breast cancer and underscore the value of women living with the disease. Through her work, Carla continues to drive change in the MBC community, advocating for greater awareness, better services, and hope for the future.

Bio- Grażyna began her nursing career in 2005, gaining clinical experience in critical care, emergency medicine, and oncology. Grażyna is the Specialist Oncology Nurse and was the first Breast Cancer Nurse in Poland. Since 2018, she has remained dedicated to this role, currently working in Breast Cancer Chemotherapy Day Unit at the University Clinical Centre in Gdańsk.

 

 

In 2023, Grażyna accomplished her PhD at the Medical University of Gdańsk, where she continues to share her expertise and passion for breast cancer with nursing and medical students as a lecturer.  

 

 

Beyond her clinical role, Grażyna actively advocates for breast cancer nursing in Poland and participates in initiatives aimed at raising awareness about breast cancer and its prevention among Polish women. She is a member of the Polish Society of Oncology and holds the position of Vice President for the local Polish Oncology Nurses Association.

Director of the Early Drug Development Division and Co-Chair for the Experimental Therapeutics Program at the European Institute of Oncology, a comprehensive cancer center in Milan, Italy. He is a steering committee member of the Department of Oncology and Hemato-Oncology at the University of Milan. Moreover, he is a member of the Italian National Health Council, serving as an adviser to the Ministry of Health for cancer policy issues.

Prof. Giuseppe Curigliano has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

AstraZeneca, BMS, Celcuity, Daiichi Sankyo, Exact Sciences, Menarini, Merck, Novartis, Pfizer, Roche, Ellipsis, Astellas, Blueprint Medicines, BMS, Kymab, Philogen, Relay Therapeutics and Sanofi​

Head of the International Breast Cancer Centre (IBCC) in Barcelona, founding partner of Medica Scientia innovation Research (MedSIR), a company involved in the clinical development of clinical trials. Member of the Scientific Committee of the ESMO and EBCC.

Prof. Javier Cortés has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Roche , AstraZeneca, Seattle Genetics, Daiichi Sankyo, Lilly, Merck Sharp & Dohme, Leuko, Bioasis, Clovis Oncology, Boehringer Ingelheim, Ellipses, Hibercell, BioInvent, Gemoab, Gilead, Menarini, Zymeworks, Reveal Genomics, Scorpion Therapeutics, Expres2ion Biotechnologies, Jazz Pharmaceuticals, Abbvie, BridgeBio, Biontech, Biocon, Circle Pharma, Delcath Systems, Roche, Novartis, Eisai, Pfizer, Lilly, Merck Sharp & Dohme, Daiichi Sankyo, Astrazeneca, Gilead, Stemline Therapeutics.

Sara Tolaney, MD, MPH is the Chief of the Division of Breast Oncology at Dana-Farber Cancer Institute, and is internationally recognized for her research and education leadership in breast cancer. She also serves as Associate Director of the Susan F. Smith Center for Women’s Cancers and is a Senior Physician at Dana-Farber Cancer Institute and Associate Professor of Medicine at Harvard Medical School.

Dr Tolaney received her undergraduate degree from Princeton University and her medical degree from UC San Francisco. She subsequently completed her residency in Internal Medicine at Johns Hopkins University, and fellowships in hematology and medical oncology at Dana-Farber Cancer Institute. She obtained her Masters in Public Health from Harvard School of Public Health.

Her research focuses on the development of novel therapies in the treatment of breast cancer and developing more effective and less toxic treatment approaches. Her work has demonstrated that a relatively low risk regimen is beneficial in women with early stage node-negative HER2-positive cancers, and this works has been incorporated into national and international guidelines. She has developed several follow-up studies looking at novel approaches to early stage HER2-positive disease and has also played a significant role in development of cdk 4/6 inhibitors, antibody drug conjugates, and immunotherapy in breast cancer. She currently chairs several registration studies in these areas and also leads many investigator-initiated trials. She is the author of over 150 peer-reviewed publications with manuscripts included in many prestigious journals such as the New England Journal, Lancet Oncology, Journal of Clinical Oncology, and JAMA Oncology.

Dr Sara Tolaney has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Consulting or Advisory Role: Novartis, Pfizer, Merck, Eli Lilly, AstraZeneca, Genentech/Roche, Eisai, Sanofi, Bristol Myers Squibb, Seattle Genetics, CytomX Therapeutics, Daiichi Sankyo, Gilead, Ellipses Pharma, 4D Pharma, OncoSec Medical Inc., BeyondSpring Pharmaceuticals, OncXerna, Zymeworks, Zentalis, Blueprint Medicines, Reveal Genomics, ARC Therapeutics, Infinity Therapeutics, Myovant, Zetagen, Umoja Biopharma, Menarini/Stemline, Aadi Biopharma, Bayer

Research Funding: Genentech/Roche, Merck, Exelixis, Pfizer, Lilly, Novartis, Bristol Myers Squibb, Eisai, AstraZeneca, Gilead, NanoString Technologies, Gilead, Seattle Genetics, OncoPep

Shaheenah Dawood is a Consultant medical oncologist and professor in clinical oncology in the United Arab Emirates. She trained in medical oncology at McGill University Hospitals in Canada and subspecialized in breast cancer management at MD Anderson Cancer Center. During her training she was awarded multiple scholar in training awards and ASCO merit awards. She has served as an editorial fellow at the New England Journal of medicine and has an MPH from the Harvard School of Public Health. She has over 100 papers to her credit including 50 peer review original articles, 30 review articles and 12 book chapters. She serves as a reviewer for multiple journals. She currently leads the oncology clinical trials program at Mediclinic City Hospital Dubai. She also serves as president of the Excellence in oncology summit that is held annually in Dubai and is co president of the Asia pacific breast cancer summit (ABCS) and Asia pacific gastrointestinal cancer summit (APGCS). She has also recently launched the international BRCA forum and young womens forum.

Prof. Shaheenah Dawood has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

MSD, Roche, BMS, New Bridge, Novartis, llilly , Pfizer, Caris, Merck, Jaansen, Ipsen,Astrazeneca, Zulleg Pharma
pdf Download BluePrint - PDF clock
Programme summary
Share this programme
x-twitter
This educational programme is supported by an Independent Educational Grant from AstraZeneca.
Supporter Acknowledgement
This educational programme is supported by an Independent Educational Grant from AstraZeneca.
Endorsement
EONS - European Oncology Nursing Society Europa Donna
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
BREAST CANCER CONNECT

BREAST CANCER CONNECT is an initiative of COR2ED, supported by an Independent Educational Grant from Menarini Stemline Oncology, AstraZeneca and Thermo Fisher Scientific.

Meet the experts Independent IME approved
Programme summary
Watch the video now
Share this programme
x-twitter
This educational programme is supported by an Independent Educational Grant from AstraZeneca.
Supporter Acknowledgement
This educational programme is supported by an Independent Educational Grant from AstraZeneca.
Endorsement
Europa Donna EONS - European Oncology Nursing Society
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
BREAST CANCER CONNECT

BREAST CANCER CONNECT is an initiative of COR2ED, supported by an Independent Educational Grant from Menarini Stemline Oncology, AstraZeneca and Thermo Fisher Scientific.

Meet the experts Independent IME approved
Programme summary
Watch the video now
Share this programme
x-twitter
This educational programme is supported by an Independent Educational Grant from AstraZeneca.
Supporter Acknowledgement
This educational programme is supported by an Independent Educational Grant from AstraZeneca.
Endorsement
Europa Donna EONS - European Oncology Nursing Society
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
BREAST CANCER CONNECT

BREAST CANCER CONNECT is an initiative of COR2ED, supported by an Independent Educational Grant from Menarini Stemline Oncology, AstraZeneca and Thermo Fisher Scientific.

Meet the experts Independent IME approved

Other programmes of interest

podcast Video podcast
Oncology 
Metastatic breast cancer: Understanding HER2-low and HER2-ultralow classification

A novel therapeutic framework 

Experts
Dr Komal Jhaveri, Oncology Brothers (Moderators)
  • download Downloadable
    Resources
  • clock 25 MIN
  • calendar Dec 2025
  • Non-accredited Independent Medical Education
BREAST CANCER CONNECT PRECISION ONCOLOGY CONNECT
Educational programme supported by an Independent Educational Grant from AstraZeneca 
patient-support Patient Support

Episode

2

of 2

episode
Oncology Endocrinology Rare diseases 
Thriving beyond an EP-NEC diagnosis

Perspectives on treatment and care 

Experts
Jessica Thomas
Endorsed by
NET-Research-Foundation Minkhas mission
  • clock 4 MIN
  • calendar Dec 2025
  • Non-accredited Independent Medical Education
NET CONNECT
Educational programme supported by an Independent Educational Grant from Boehringer Ingelheim 
patient-support Patient Support

Episode

1

of 2

episode
Oncology Endocrinology Rare diseases 
Navigating extrapulmonary neuroendocrine carcinoma (EP-NEC)

Insights for patients and care partners 

Experts
Meredith Cummins
Endorsed by
INCA
NeuroEndocrine Cancer Australia Neuroendocrine Cancer Foundation NET-Research-Foundation
Neuroendocrine Cancer UK Minkhas mission
  • clock 5 MIN
  • calendar Dec 2025
  • Non-accredited Independent Medical Education
NET CONNECT
Educational programme supported by an Independent Educational Grant from Boehringer Ingelheim 
eks
EKS / On-demand webinar
Oncology 
ESMO 2025: Gastric and gastroesophageal cancer insights for clinical practice

On-demand materials from an Experts Knowledge Share event

Experts
Dr Elizabeth Smyth, Prof. Aziz Zaanan, Prof. Markus Moehler
Endorsed by
ESDO
Digestive Cancers Europe
ICAN international cancer advocacy network
  • download Downloadable
    Resources
  • clock 67 MIN
  • calendar Dec 2025
  • Non-accredited Independent Medical Education
GI CONNECT PRECISION ONCOLOGY CONNECT GI NURSES CONNECT
Educational programme supported by an Independent Educational Grant from Amgen.
Explore all programmes